

Lydie Trautmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3837977/publications.pdf>

Version: 2024-02-01

34
papers

4,569
citations

361413

20
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

6023
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. <i>Nature Medicine</i> , 2009, 15, 893-900.	30.7	1,519
2	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. <i>Nature Medicine</i> , 2006, 12, 1198-1202.	30.7	1,376
3	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. <i>Nature Medicine</i> , 2018, 24, 923-926.	30.7	263
4	In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a Block-and-Lock Strategy for HIV-1 Treatment. <i>Cell Reports</i> , 2017, 21, 600-611.	6.4	189
5	The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. <i>MBio</i> , 2015, 6, e00465.	4.1	188
6	Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. <i>Journal of Clinical Investigation</i> , 2014, 124, 3147-3158.	8.2	168
7	Delayed differentiation of potent effector CD8 ⁺ T cells reducing viremia and reservoir seeding in acute HIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	95
8	Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 179.	7.4	89
9	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	4.7	73
10	Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. <i>Blood</i> , 2012, 120, 3466-3477.	1.4	70
11	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	69
12	Lymphoid tissue fibrosis is associated with impaired vaccine responses. <i>Journal of Clinical Investigation</i> , 2018, 128, 2763-2773.	8.2	55
13	Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation. <i>Journal of Immunology</i> , 2012, 188, 1156-1167.	0.8	38
14	Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription. <i>MBio</i> , 2019, 10, .	4.1	38
15	Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005777.	4.7	37
16	T Cell Immunity and Zika Virus Vaccine Development. <i>Trends in Immunology</i> , 2017, 38, 594-605.	6.8	32
17	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 108-117.	2.1	31
18	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. <i>Journal of Clinical Investigation</i> , 2020, 130, 2845-2858.	8.2	31

#	ARTICLE	IF	CITATIONS
19	Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. <i>Journal of Infectious Diseases</i> , 2018, 218, 1453-1463.	4.0	28
20	Kill. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 409-416.	3.8	24
21	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , 2020, 130, 3299-3304.	8.2	24
22	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. <i>Journal of Virus Eradication</i> , 2020, 6, 100004.	0.5	23
23	Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells. <i>Journal of Immunological Methods</i> , 2012, 375, 252-257.	1.4	17
24	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2022, 208, 54-62.	0.8	16
25	Role of T Lymphocytes in HIV Neuropathogenesis. <i>Current HIV/AIDS Reports</i> , 2019, 16, 236-243.	3.1	15
26	The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. <i>PLoS Pathogens</i> , 2022, 18, e1010245.	4.7	11
27	CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 315-324.	3.8	10
28	Modeling HIV-1 Latency Using Primary CD4 ⁺ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
29	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	9
30	Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner. <i>Frontiers in Immunology</i> , 2020, 11, 1430.	4.8	7
31	CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir. <i>Journal of Immunology</i> , 2020, 205, 699-707.	0.8	7
32	Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS. <i>Frontiers in Immunology</i> , 2021, 12, 682182.	4.8	3
33	Transcriptional and Immunologic Correlates of Response to Pandemic Influenza Vaccine in Aviremic, HIV-Infected Children. <i>Frontiers in Immunology</i> , 2021, 12, 639358.	4.8	2
34	Transforming dysfunctional CD8+ T cells into natural controller-like CD8+ T cells: can TCF-1 be the magic wand?. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	1